Vistagen Therapeutics (VTGN) Research & Development (2011 - 2026)

Vistagen Therapeutics has disclosed Research & Development across 16 years of filings, most recently posting $10.9 million for Q2 2026.

• In Q2 2026, Research & Development fell 6.61% year-over-year to $10.9 million; the TTM figure through Jun 2026 stood at $54.1 million (up 24.65% YoY), while the FY2026 annual figure was $55.0 million, up 39.62% from the prior year.
• Research & Development came in at $10.9 million for Q2 2026 at Vistagen Therapeutics, down from $13.1 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $15.9 million in Q3 2025 to a low of $3.9 million in Q3 2023.
• Average Research & Development over 5 years is $10.1 million, with a median of $10.6 million recorded in 2024.
• Year-over-year, Research & Development surged 180.16% in 2022 and slumped 72.55% in 2023.
• Over 5 years, Research & Development stood at $6.9 million in 2022, then sank by 33.81% to $4.5 million in 2023, then surged by 149.17% to $11.3 million in 2024, then gained by 25.81% to $14.2 million in 2025, then declined by 23.32% to $10.9 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $10.9 million in Q2 2026, $13.1 million in Q1 2026, and $14.2 million in Q4 2025.